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This study was designed to identify the multivariate effect of clinical risk factors on high on-
treatment platelet reactivity (HPR) and 12 months major adverse events (MACE) under
treatment with aspirin and clopidogrel in patients undergoing non-urgent percutaneous cor-
onary intervention (PCI).
Methods
739 consecutive patients with stable coronary artery disease (CAD) undergoing PCI were
recruited. On-treatment platelet aggregation was tested by light transmittance aggregome-
try. Clinical risk factors and MACE during one-year follow-up were recorded. An indepen-
dent population of 591 patients served as validation cohort.
Results
Degree of on-treatment platelet aggregation was influenced by different clinical risk factors.
In multivariate regression analysis older age, diabetes mellitus, elevated BMI, renal func-
tion and left ventricular ejection fraction were independent predictors of HPR. After weigh-
ing these variables according to their estimates in multivariate regression model, we
developed a score to predict HPR in stable CAD patients undergoing elective PCI
(PREDICT-STABLE Score, ranging 0-9). Patients with a high score were significantly more
likely to develop MACE within one year of follow-up, 3.4% (score 0-3), 6.3% (score 4-6)
and 10.3% (score 7-9); odds ratio 3.23, P=0.02 for score 7-9 vs. 0-3. This association was
confirmed in the validation cohort.
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Conclusions
Variability of on-treatment platelet function and associated outcome is mainly influenced by
clinical risk variables. Identification of high risk patients (e.g. with high PREDICT-STABLE
score) might help to identify risk groups that benefit from more intensified antiplatelet regi-
men. Additional clinical risk factor assessment rather than isolated platelet function-guided
approaches should be investigated in future to evaluate personalized antiplatelet therapy in
stable CAD-patients.
Introduction
Guidelines currently recommend dual platelet inhibition with aspirin and clopidogrel to pre-
vent post-procedural adverse events after elective percutaneous coronary intervention (PCI)
with stent-implantation [1]. There has been cumulative evidence in the past that interindividu-
al variability of response to clopidogrel is high, mainly due to clinical risk factors and genetic
variability of drug-metabolism [2–4]. There has been consensus that high-on-treatment plate-
let reactivity is associated with major adverse atherothrombotic events including stent throm-
bosis after PCI [5]. Presently new drugs with higher platelet inhibition and lower
interindividual variability are available in clinical practice, however are not approved in stable
coronary artery disease (CAD). Intensified platelet inhibition solely guided by platelet function
analysis has been shown unsuccessful in reducing cardiovascular risk [6–8]. Thus, additional
risk assessment is needed to identify patients with stable CAD who might benefit from en-
hanced platelet inhibition in the chronic phase.
Previously, we established a simple risk tool—PREDICT (Residual Platelet Aggregation after
Deployment of Intracoronary Stent) score, based on clinical variables that are easily available in
daily routine to identify patients at risk for high on-treatment platelet reactivity (HPR) in unse-
lected cohort of patients undergoing PCI [9]. The score encompasses 5 different variables in-
cluding acute coronary syndrome on admission, older age, diabetes mellitus, renal and left
ventricular function impairment. After weighing these variables according to their effects size
in multivariate analysis, the score ranged from 0–9 with higher score levels being significantly
associated with both HPR and cardiovascular outcome. To date, tools to assess atherothrombo-
tic risk after non-urgent PCI are lacking. Therefore, the aim of the present study was a) to iden-
tify clinical risk factors that are associated with on-treatment platelet reactivity and outcome
and b) to investigate the added value of on-treatment platelet reactivity compared to clinical
risk factor assessment in a selected population of patients with stable CAD undergoing PCI.
Methods
Study population
Patients with symptomatic coronary artery disease undergoing non-urgent coronary stent im-
plantation were consecutively enrolled at the Department of Cardiology, University Hospital,
Tübingen fromMarch 2005 till May 2008. Inclusion criteria were age older than 18 years,
planned coronary intervention and willing consent. Exclusion criteria were known platelet
function disorders or indication for longterm oral anticoagulation. All patients were evaluated
by platelet function analysis by Light Transmission Aggregometry (LTA) under maintenance
therapy at a median of 24 hours after PCI. For the current analysis only patients with stable
CAD were included and examined for clinical variables influencing HPR.
PREDICT-STABLE Score
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For the validation cohort, stable CAD patients with the same inclusion criteria presented be-
tween February 2011 and October 2012 at the University Hospital Tübingen, Germany
(n = 354) and between March 2007 and September 2008 at the Department of Cardiology,
Medical University of Vienna, Austria (n = 237) were analysed. The characteristics of the Aus-
trian cohort are described elsewhere [10]. Platelet function was assessed using Multiple Elec-
trode Aggretometry (MEA).
The trial was conducted in accordance with the principles of good clinical practice and the
Declaration of Helsinki. All patients gave written informed consent. Approval was obtained by
the ethical committee of the University Tübingen.
Platelet function analysis
Platelet function analysis by Light Transmission Aggregometry (LTA) was performed at a
median of 24 hours after a 600mg loading dose of clopidogrel was given. According to previ-
ous results, maximum platelet inhibition can be detected at this time point [9,11,12]. Venous
blood samples collected in 3.8% citrate plasma were centrifuged at 150 x g for 10 minutes to
obtain platelet-rich plasma (PRP). After additional centrifugation at 2000 x g for 10 minutes
platelet-poor plasma (PPP) was obtained. By adding homologous PPP, platelet concentration
of PRP was adjusted to 2 x 105 μL-1. After administration of 20 μmol L-1 adenosine diphos-
phate (ADP), per cent platelet aggregation was assessed with the turbodimetric method using
a ChronologLumiaggregometer with Aggro-Link Software. Platelet aggregation measured 5
min after addition of ADPwas used to determine on-treatment platelet reactivity. HPR was
defined as the highest quartile of measured platelet reactivity in the examined population as
reported previously [9,13–15].
In the validation cohort platelet function was analysed by Multiple Electrode Aggretometry
(MEA). Samples of whole blood anticoagulated with hirudin were collected after initial clopi-
dogrel loading. Platelet function was assessed after stimulation with 6.4 μMADP, by a new
generation impedance aggregometer (Multiplate Analyzer, VerumDiagnostica GmbH, Mu-
nich, Germany). Platelet activity was reported as area under the curve aggregation units (AUC)
as described previously. A good correlation between MEA und LTA was shown before[16].
Follow-up
Patients were followed up by telephone interview 12 month after enrollment. Incidence of
major cardiovascular events (MACE) including death, myocardial infarction and ischemic
stroke were assessed by telephone interview. An acute myocardial infarction (AMI) was diag-
nosed by a rise and/or fall of cardiac biomarker values [cardiac troponin (cTn)] with at least
one value above the 99th percentile upper reference limit and with at least one of the following:
symptoms of ischaemia, new or presumed new significant ST-segment–T-wave (ST–T)
changes or new left bundle branch block, development of pathological Q waves in the ECG, im-
aging evidence of new loss of viable myocardium or new regional wall motion abnormality, or
identification of an intracoronary thrombus by angiography [17].Telephone interviewers were
blinded with respect to the results of platelet aggregation test.
Statistical analysis
Continuous data with normal distribution are presented as mean ± SD, not normally distribut-
ed data as median and interquartile range. Categorical variables are expressed as number (%).
Equality of distribution of categorical variables between subgroups was analyzed by chi-
squared test. Continuous data with non-normal distribution were compared by Mann-Whit-
ney test. For analysis of clinical predictors for HPR univariate logistic regression analysis was
PREDICT-STABLE Score
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used. The highest quartile of on-treatment platelet reactivity assessed by LTA was used as the
dependent variable. Clinical variables available in daily routine were included in the model as
independent variables. Variables included age, gender, diabetes mellitus, hypertension, hyper-
lipidemia, smoking history, adiposity (BMI>30), reduced left ventricular function, reduced
renal function and multivessel disease. For continuous variables cut-off values with highest
sensitivity and specificity were determined by receiver operating characteristic (ROC) curves.
Thus categorical variables were created that were used for development of the risk score. Fac-
tors with a significance level of P<0.1 in univariate analysis were included into multivariate
model. Multivariate analysis was used then to identify independent predictors of HPR and to
create the PREDICT-STABLE score. According to effect size (odds ratio) of relevant clinical
predictors for HPR in multivariate analysis, a weighed score was developed. For comparison of
MACE between different score levels, Kaplan-Meier curves were constructed and groups were
compared by the log-rank test. For comparison of categorical and continuous data a two-sided
P value of<0.05 was considered statistically significant. All statistical tests were performed
with IBM SPSS Statistics software, version 21.0.
Results
Baseline characteristics
2226 patients were consecutively enrolled in the study. In 1549 patients platelet reactivity mea-
surement by LTA was available, from these patients 810 (52.3%) were treated for acute coro-
nary syndrome (unstable angina pectoris, non-ST- and ST-elevation myocardial infarction)
and 739 (47.7%) for stable CAD, the latter were included in the analysis. Baseline patients’
characteristics are shown in Table 1. 30% of patients suffered from diabetes, 42.1% had reduced
left ventricular function, 74.1% had multivessel disease. 65.7% were treated with bare metal
stents, 24.5% with drug-eluting stents, 9.7% with both stent-types. Characteristics of study pop-
ulation according to quartiles of platelet reactivity are shown in Table 1. Patients in the highest
quartile were significantly older, had a higher body mass index, had more often diabetes melli-
tus and renal impairment (P<0.05).
Risk factors of HPR and development of the risk score
For continuous variables following cut offs with best sensitivity and specificity were calculated
by ROC curves: age of 63 years, left ventricular function of 55% and serum creatinin level of 1.1
g/dL. These cut offs were used to create categorical variables for the analysis. In univariate
analysis, the following factors were significant predictors of HPR (P<0.1, Table 2) and were in-
cluded in multivariate analysis: age> 63 years, female gender, diabetes mellitus, adiposity
(BMI>30 kg/m2), reduced left ventricular (LV) function (LV ejection fraction< 55%), reduced
renal function (serum creatinin> 1.1 g/dL). In multivariate analysis age, diabetes mellitus, adi-
posity, reduced left ventricular function and reduced renal function remained significant pre-
dictors of HPR whereas female gender was no longer significant (Table 3). According to effect
size (odds ratio) of relevant clinical predictors of HPR in multivariate analysis, a weighed score
was developed. In detail age> 63 years was weighted by factor 3, diabetes and adiposity by fac-
tor 2, reduced left ventricular function and reduced renal function by factor 1 (odds ratios 2.11,
1.78, 1.86, 1.54 and 1.48 respectively). Thus, a score ranging from 0–9 was developed (Table 3).
The prevalence for a PREDICT-STABLE score of 0–3 was 32.3%, 50% for a score of 4–6 and
17.7% for a score of 7–9. Fig. 1A shows per cent HPR in each score level: 14%, 23.7% and
43.4% for PREDICT-STABLE score 0–3, 4–6 and 7–9, respectively.
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Follow-up
Follow-up was available for 686 patients (93%). MACE occurred in 42 (5.7%) of patients. Medi-
an follow up was 152 (91–400) days. There were 3.0% myocardial infarctions, 1.4% ischemic
strokes and 1.9% deaths in the study population. Fig. 1B shows distribution of MACE according
to PREDICT-STABLE score. There was a steady increase of MACE after 1 year follow up with
higher PREDICT-STABLE score i.e. 3.4% in patients with a score of 0–3, 6.3% in patients with a
score of 4–6 and 10.3% in patients with a score of 7–9 (P = 0.20 and 0.02 respectively for com-
parison with the score group 0–3). Patients with high PREDICT-STABLE score (7–9) had about
Table 1. Characteristics of the study population according to quartile of HPR.
Baseline demographics Patients N = 739 Quartile of platelet reactivity P*
1 2 3 4
Gender m/f (%) 77.5/22.5 75.5/24.5 80.7/19.3 81/19 72.8/27.2 0.081
Age (years) 69 (61–75) 67.0 (57–74) 68.0 (59.0–74.0) 70.0 (63.0–74.0) 69.0 (64.5–74.5) 0.051
Body mass index 27.4 (25.1–30.5) 26.1 (24.3–26.1) 27.1 (25.46–30.1) 28.4 (25.8–30.75) 28.3 (26.04–31.77) 0.001
Adiposity BMI>30 (%) 24.5 18.7 25.3 32.7 36.8 0.007
Hypertension (%) 82.9 80.1 81.8 86.4 87.6 0.129
Smoking history 39.0 42.4 40.8 38.9 38.1 0.536
Hyperlipidemia (%) 73.9 73.7 67.4 80.4 74.0 0.969
Diabetes mellitus (%) 30.9 22.6 27.1 34.2 41.0 0.001
Serum creatinin mg/dL 1.0 (0.9–1.2) 1.1 (0.9–1.2) 1.1 (0.9–1.3) 1.0 (0.9–1.28) 1.1 (0.9–1.4) 0.021
Left ventricular function (%) 55.7 (49–65) 55.7 (50–58) 60 (49–65) 60 (49–65) 54.5 (46–65) 0.083
Medication
Statins (%) 88.9 87.0 90.2 91.4 86.9 0.367
ACE- Inhibitors(%) 77.4 77.6 76.8 79.3 76.0 0.615
Angiotensin receptor blockers (%) 11.6 13.7 8.5 16.5 14.9 0.514
β-blockers (%) 91.0 93.8 89.6 90.9 89.6 0.501
Multivessel disease 74.1 69.7 74.7 85.2 76.9 0.424
Bare metal stents/ drug-eluting
stents/both
65.7/24.5/9.7 66.7/22.6/10.7 61.3/27.5/11.3 63.6/27.2/9.3 71.6/20.6/7.7 0.08/0.20/0.33
* for quartile 4 vs. 1–3.
doi:10.1371/journal.pone.0121620.t001
Table 2. Univariate analysis of risk predictors for HPR.
Quartile of platelet reactivity 1–3 4 (HPR) Coefficient B Odds ratio (95% CI) P
Age (> 63 years) (%) 69.4 82.6 0.74 2.09 (1.37–3.20) 0.001
Gender m/f (%) 79.0/21.0 72.8/27.2 0.34 1.41 (0.96–2.06) 0.082
Diabetes mellitus (%) 27.9 41 0.58 1.79 (1.26–2.55) 0.001
Hypertension (%) 82.8 87.6 0.38 1.47 (0.89–2.42) 0.131
Hyperlipidemia (%) 73.9 74 0.01 1.01(0.69–1.48) 0.969
Smoking (%) 40.7 38.1 -0.11 0.54 (0.63–1.27) 0.536
Adiposity BMI>30 (%) 25.5 36.8 0.53 1.70 (1.16–2.51) 0.007
Reduced left ventricular function EF<55 (%) 41.5 51.4 0.39 1.48 (1.06–2.08) 0.02
Reduced renal function (Serumcreatinin> 1.1 g/dL in %) 46.5 61.5 0.61 1.84 (1.29–2.63) 0.001
Multivessel disease* (%) 74.9 71.9 -0.15 0.86 (0.59–1.25) 0.424
* defined as 50% or greater stenoses in at least one major epicardial vessel.
doi:10.1371/journal.pone.0121620.t002
PREDICT-STABLE Score
PLOS ONE | DOI:10.1371/journal.pone.0121620 March 23, 2015 5 / 13
3 times higher probability to develop MACE than patients with score 0–3 (odds ratio 3.23,
P = 0.02 for Score 7–9 vs. 0–3; odds ratio 1.90, P = 0.20 for Score 4–6 vs. 0–3). Early (30 days)
and late outcomes are shown in Table 4. After 30 days there was numerically highest MACE
rate for highest PREDICT STABLE score levels (7–9), although statistically not significant. Dif-
ferences were consistent for all MACE components. Similarly, in Kaplan-Meier analysis a higher
PREDICT-STABLE score level was associated with significantly higher MACE rate in compari-
son to a low score (Fig. 2, P = 0.01), however there was no difference in MACE between patients
with HPR and patients with adequate on-treatment platelet reactivity (Fig. 3, P = 0.69).
ROC curve analysis showed that PREDICT-STABLE score improved prediction of
12-month MACE compared to on-treatment platelet reactivity alone as measured by the area
under the curve (AUC 0.62, P = 0.02 versus 0.60, P = 0.04). However, there was no relevant
benefit for risk prediction by combining both on-treatment platelet reactivity and PREDICT--
STABLE score (AUC 0.63, P = 0.01, Fig. 4).
Validation of the PREDICT-STABLE score in an independent cohort
For validation of the PREDICT-STABLE score 591 patients with same inclusion criteria as the
study population were enrolled (Table 5). Similar to the exploratory cohort we could show a
significant correlation of MACE with higher PREDICT-STABLE score levels (Fig. 5A). Fur-
thermore, we could show that patients with higher PREDICT-STABLE score have significant
higher platelet reactivity assessed by MEA (Fig. 5B). In analogy to the discovery cohort, combi-
nation between on-treatment platelet reactivity assessed by MEA and the PREDICT-STABLE
score did not improve risk prediction for MACE in ROC-analysis.
Table 3. Multivariate analysis of risk predictors for HPR.
Variables Coefficient B Odds ratio (95% CI) P PREDICT-STABLE
Age (> 63 years) 0.745 2.11 (1.26–3.53 0.005 3
Female gender 0.381 1.46 (0.93–2.31) 0.102 -
Diabetes mellitus 0.575 1.78 (1.19–2.65) 0.005 2
Adiposity (BMI>30) 0.622 1.86 (1.22–2.86) 0.004 2
Reduced left ventricular function EF<55 0.431 1.54 (1.03–2.31) 0.037 1
Reduced renal function (Serumcreatinin> 1.1 g/dL) 0.391 1.48 (0.97–2.25) 0.067 1
doi:10.1371/journal.pone.0121620.t003
Fig 1. A Incidence of HPR (%) according to PREDICT-STABLE Score B Incidence of MACE according to PREDICT-STABLE Score. P-values for
comparison with PREDICT-STABLE score 0–3
doi:10.1371/journal.pone.0121620.g001
PREDICT-STABLE Score
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Discussion
Variability of individual response to antiplatelet therapy remains a challenging clinical prob-
lem. There is still a significant number of patientsafter elective coronary PCI having complicat-
ing adverse cardiovascular events [18–21]. This may be partly explained by variability of
response to antiplatelet therapy. According to current data there are about 40% of patients con-
sidered to be low responders to clopidogrel depending on definition and particular platelet
function assay [6,7]. The prognostic impact of high on-treatment platelet reactivity (HPR) for
the occurrence of serious cardiovascular events after PCI, particularly stent thrombosis has
been demonstrated in several studies [12–14,22,23]. However, there is currently no evidence
that platelet function guided approaches lead to improvement of clinical outcome. To date,
randomized trials investigating the effect of antiplatelet therapy adjusted to the results of
Table 4. Clinical outcome after 30 days and 1 year of follow up according to PREDICT-STABLE Score.
30 days/1 year N = 686 PREDICT-STABLE 0–3 PREDICT-STABLE 4–6 PREDICT-STABLE 7–9
MACE 1.8/5.7% 0.0/3.4% 1.4/6.3% 3.1/10.3%*
Myocardialinfarction 0.7/3.0% 0.0/1.7% 0.7/3.5% 1.0/5.2%
Ischemic stroke 0.3/1.4% 0.0/0.6% 0.4/1.8% 0.0/3.1%
Death 0.8/1.9% 0.0/1.1% 0.4/1.4% 2.1/4.1%
Stent thrombosis
Definite 0.4/0.5% 0.0/0.6% 0.0/0.0% 3.1/3.1%
Probable 0.5/2.3% 0.0/0.6% 1.1/3.2% 0.0/3.1%
Possible 0.1/0.8% 0.0/0.6% 0.0/0.0% 0.1/2.1%
* P<0.05 in comparison with PREDICT-STABLE 0–3.
doi:10.1371/journal.pone.0121620.t004
Fig 2. Kaplan-Meier analysis for incidence of MACE according PREDICT-STABLE Score (comparison
of score levels 0–3 with 7–9).
doi:10.1371/journal.pone.0121620.g002
PREDICT-STABLE Score
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platelet function testing have not shown an effect regarding improvement of outcome (GRAV-
ITAS, TRIGGER-PCI, ARCTIC trial) either due to a weak active control arm (GRAVITAS) [6]
or an overall low risk population (TRIGGER-PCI, ARCTIC) [7,8]. Therefore, the characteriza-
tion of platelet function testing as a modifiable risk factor remains questionable. An association
between genetic and non-genetic factors and HPR under dual antiplatelet therapy has been de-
scribed previously [24–35]. Thus, it is in the focus of the on-going debate whether HPR is a
“by-stander” of the overall cardiovascular risk rather than representing an independent modifi-
able parameter associated with clinical prognosis. Risk after elective non-urgent PCI is general-
ly low. Some risk tools have been evaluated to characterize peri-procedural/in-hospital risk in
stable CAD patients [36,37]. However, these scores have not been evaluated for their associa-
tion with on-treatment platelet reactivity and long-term risk after elective PCI.
In own preliminary work we developed a score (PREDICT score) to estimate the likehood
for HPR utilizing easily available non-genetic risk factors in an unselected cohort of patients
with symptomatic coronary artery disease (stable CAD/ACS) [9]. The score contains distinct
and easily available patient factors. In the present analysis, we were able to develop a modified
score (PREDICT-STABLE Score) focusing on a sub-population of patients with stable CAD in
a large retrospective cohort of patients. In our study age, adiposity defined by elevated
BMI>30 kg/m2, diabetes mellitus, reduced renal function and reduced left ventricular func-
tion were associated with HPR. These findings are in line with previous studies. Influence of
higher age on clopidogrel response could be demonstrated in several trials. As an explanation
reduced liver function and hence slower activation of clopidogrel prodrug and higher baseline
Fig 3. Kaplan-Meier analysis for incidence of MACE according platelet function analysis (comparison of HPR vs. adequate on-treatment response
in Patients with high PREDICT-STABLE Score 7–9).
doi:10.1371/journal.pone.0121620.g003
PREDICT-STABLE Score
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platelet reactivity are discussed [30,31]. In obese patients drug underdosing and decreased
CYP3A4 activity is a possible explanation for lower response [32–34]. Enhanced vascular in-
flammation and platelet activation due to hyperglycemia, impaired lipid metabolism and oxi-
dative stress can cause higher on-treatment platelet reactivity on antiplatelet treatment in
diabetic individuals [26,27]. Some studies could demonstrate influence of reduced renal
Fig 4. Comparison of predictive value for on-treatment platelet reactivity (PR), PREDICT-STABLE
Score alone and in combination by ROC curve analysis.
doi:10.1371/journal.pone.0121620.g004
Table 5. Baseline characteristics of the validation cohort.
Baseline demographics N = 591
Gender m/f (%) 75/25
Age (years) 68 (59–76)




Diabetes mellitus (%) 35.3
Reduced renal function (Serumcreatinin> 1.1 g/dL in %) 33.0
Reduced left ventricular function (%) 34.5
Medication
Statins (%) 66.8
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function on clopidogrel responsiveness. Altered platelet function and reduced sensitivity to an-
tiplatelet drugs through complex disturbances (increased platelet turnover rate, impaired ab-
sorption or drug metabolism, procoagulant factors) in renal insufficient patients are supposed
mechanisms [28,29,38,39]. In this context, individuals with moderate renal impairment might
rather benefit from more intensified longterm P2Y12 inhibition [40]. Patients with heart failure
show decreased gastrointestinal absorption of antiplatelet drugs, elevated markers of platelet
activation including thromboglobulin, Platelet Factor 4, P-Selectin and platelet-derived adhe-
sion molecules and increased platelet volume [35,41].
With the present analysis, we demonstrate that patients with a high PREDICT-STABLE
Score (e.g.> 6 points) have significantly increased probability of HPR and higher rate of major
adverse cardiovascular events. Moreover we could validate these findings in a separate consecu-
tive cohort of patients with stable CAD. Of note, patients with a score of> 6 developed similar
12-month rate for atherothrombotic events as in clopidogrel-treated arms of recent major
ACS-trials (Fig. 1B) [42,43]. Additionally, we did not find any improvement of prediction by
adding on-treatment platelet reactivity to assessment of clinical risk factors for HPR and ather-
othrombotic events. This adds to the hypothesis that HPR represents more a bystander of over-
all atherothrombotic risk and partly explains the previous unsuccessful approaches to use
platelet reactivity as a modifiable risk factor alone. This is especially true for long-term progno-
sis after PCI in stable CAD patients in contrast to the ACS setting when there is a biologically
causative relationship between high platelet reactivity and early atherothrombotic events in-
cluding stent thrombosis. In line with these observations are previous results from studies in-
cluding stable CAD patients and medically managed ACS patients revealing that HPR has no
incremental benefit for risk prediction over established clinical risk factors for MACE [44,45].
Hence, additional clinical risk factor assessment rather than isolated platelet function-guided
approaches should be investigated in future to evaluate personalized antiplatelet strategies in
stable patients with coronary artery disease. It is tempting to speculate, that the score might
help to identify patients at high risk (e.g. patients with high PREDICT-STABLE score) that
benefit not only from more intensified antiplatelet regimen (ticagrelor, prasugrel, low dose riv-
aroxaban or vorapaxar) [42,43,46,47] but also from a more universal strategy to modify risk
profile thus reducing atherothrombotic events. Interventional studies are needed to character-
ize the effects of these approaches to demonstrate effects on thromboischemic and bleeding
risk in selected high risk stable CAD patients.
Fig 5. A Incidence of MACE according to PREDICT-STABLE Score in the validation cohort B Platelet reactivity assessed by MEA according to
PREDICT-STABLE Score in the validation cohort. P-values for comparison with PREDICT-STABLE score 0–3.
doi:10.1371/journal.pone.0121620.g005
PREDICT-STABLE Score
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Limitations
Antiplatelet drug response is multifactorial. In our score we assessed clinical risk variables
which can be easily obtained from patients’ clinical examination. Although LTA is still the
gold-standard to investigate ADP-induced aggregation, antiplatelet drug response is more
complex than monitored by a single platelet function test. Additionally, several genetic factors
affect response to clopidogrel (polymorphisms of CYP3A4, CYP2C19, GPIa, P2Y12, GPIIIa,
CES1) and these were not included in the present study. There can be more unknown factors
which were not considered in the present score. On the contrary, avoiding extensive laboratory
testing makes the score valuable for application in clinical situations when rapid information
and risk assessment is needed.
Author Contributions
Analyzed the data: MD ES MS JS-MMG TG. Wrote the paper: MDMG TG. Acquisition of
data: MD ET FS AK DT KALM JS-M AT. Critical revision of the manuscript for important in-
tellectual content: DT KALM ET AK FS ES MS AT JS-M. Statistical analysis: MD TG. Study su-
pervision: TG. Final approval: TG.
References
1. WijnsW, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revasculari-
zation. Eur Heart J. 2010; 31: 2501–2555. doi: 10.1093/eurheartj/ehq277 PMID: 20802248
2. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability,
drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107: 2908–2913.
PMID: 12796140
3. Müller I, Besta F, Schulz C, Massberg S, Schönig A, Gawaz M. Prevalence of clopidogrel non-respond-
ers among patients with stable angina pectoris scheduled for elective coronary stent placement.
Thromb Haemost. 2003; 89: 783–787. PMID: 12719773
4. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet respon-
siveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005; 45: 246–251. PMID: 15653023
5. Tantry US, Bonello L, Aradi D, Price MJ, Jeong Y-H, Angiolillo DJ, et al. Consensus and update on the
definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and
bleeding. J Am Coll Cardiol. 2013; 62: 2261–2273. doi: 10.1016/j.jacc.2013.07.101 PMID: 24076493
6. Price MJ, Berger PB, Teirstein PS, Tanguay J-F, Angiolillo DJ, Spriggs D, et al. Standard- vs high-dose
clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS
randomized trial. JAMA J AmMed Assoc. 2011; 305: 1097–1105.
7. Collet J-P, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, et al. Bedside monitoring to adjust anti-
platelet therapy for coronary stenting. N Engl J Med. 2012; 367: 2100–2109. doi: 10.1056/
NEJMoa1209979 PMID: 23121439
8. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, et al. A randomized trial of prasugrel
versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous cor-
onary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Plate-
let Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative
TherapyWith Prasugrel) study. J Am Coll Cardiol. 2012; 59: 2159–2164. doi: 10.1016/j.jacc.2012.02.
026 PMID: 22520250
9. Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, Dietz K, et al. The Residual Platelet Aggregation
after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost JTH. 2008; 6: 54–61.
PMID: 17949474
10. Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, et al. Phenotyping vs. gen-
otyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost
JTH. 2012; 10: 529–542. doi: 10.1111/j.1538-7836.2012.04639.x PMID: 22260716
11. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, et al. Time dependence of platelet in-
hibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percu-
taneous coronary intervention. Circulation. 2005; 111: 2560–2564. PMID: 15809367
12. Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B, et al. Low response to clopidogrel is
associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006; 27: 2420–
2425. PMID: 17005534
PREDICT-STABLE Score
PLOS ONE | DOI:10.1371/journal.pone.0121620 March 23, 2015 11 / 13
13. Spiliopoulos S, Pastromas G, Katsanos K, Kitrou P, Karnabatidis D, Siablis D. Platelet responsiveness
to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact
and optimal cutoff value of on-treatment high platelet reactivity. J Am Coll Cardiol. 2013; 61: 2428–
2434. doi: 10.1016/j.jacc.2013.03.036 PMID: 23602777
14. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, et al. Platelet reactivity in patients and
recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol.
2005; 46: 1820–1826. PMID: 16286165
15. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, et al. Clopidogrel effect on platelet re-
activity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol. 2005; 46:
1827–1832. PMID: 16286166
16. Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schömig A, et al. Assessment of ADP-induced
platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry
before and after clopidogrel treatment. Thromb Haemost. 2008; 99: 121–126. doi: 10.1160/TH07-07-
0478 PMID: 18217143
17. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition
of myocardial infarction. Eur Heart J. 2012; 33: 2551–2567. doi: 10.1093/eurheartj/ehs184 PMID:
22922414
18. Neumann FJ, Gawaz M, Ott I, May A, Mössmer G, Schömig A. Prospective evaluation of hemostatic
predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol.
1996; 27: 15–21. PMID: 8522689
19. Gawaz M, Neumann FJ, Ott I, May A, Rüdiger S, Schömig A. Role of activation-dependent platelet
membrane glycoproteins in development of subacute occlusive coronary stent thrombosis. Coron Ar-
tery Dis. 1997; 8: 121–128. PMID: 9237020
20. Bucher HC, Hengstler P, Schindler C, Guyatt GH. Percutaneous transluminal coronary angioplasty ver-
sus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled
trials. BMJ. 2000; 321: 73–77. PMID: 10884254
21. Jeremias A, Kaul S, Rosengart TK, Gruberg L, Brown DL. The impact of revascularization on mortality
in patients with nonacute coronary artery disease. Am J Med. 2009; 122: 152–161. doi: 10.1016/j.
amjmed.2008.07.027 PMID: 19185092
22. Wenaweser P, Dörffler-Melly J, Imboden K, Windecker S, Togni M, Meier B, et al. Stent thrombosis is
associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol. 2005; 45: 1748–1752.
PMID: 15936599
23. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, et al. High post-treatment platelet re-
activity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascu-
lar events after stenting for acute coronary syndrome. J Thromb Haemost JTH. 2006; 4: 542–549.
PMID: 16371119
24. Hulot J-S, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of-
function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood.
2006; 108: 2244–2247. PMID: 16772608
25. Suh J-W, Koo B-K, Zhang S-Y, Park K-W, Cho J-Y, Jang I-J, et al. Increased risk of atherothrombotic
events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ Can
Med Assoc J J Assoc Medicale Can. 2006; 174: 1715–1722.
26. Geisler T, Anders N, Paterok M, Langer H, Stellos K, Lindemann S, et al. Platelet response to clopido-
grel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care. 2007; 30:
372–374. PMID: 17259513
27. Geisler T, Mueller K, Aichele S, Bigalke B, Stellos K, Htun P, et al. Impact of inflammatory state and
metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognos-
tic relevance of residual platelet aggregability in diabetics undergoing coronary interventions. Clin Res
Cardiol Off J Ger Card Soc. 2010; 99: 743–752. doi: 10.1007/s00392-011-0370-8 PMID: 21960419
28. Htun P, Fateh-Moghadam S, Bischofs C, BanyaW, Müller K, Bigalke B, et al. Low responsiveness to
clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol
JASN. 2011; 22: 627–633. doi: 10.1681/ASN.2010020220 PMID: 21273381
29. Morel O, El Ghannudi S, Jesel L, Radulescu B, Meyer N, Wiesel M-L, et al. Cardiovascular mortality in
chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to im-
paired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol. 2011; 57: 399–408. doi: 10.1016/j.jacc.2010.
09.032 PMID: 21251579
30. Cuisset T, Quilici J, Grosdidier C, Fourcade L, Gaborit B, Pankert M, et al. Comparison of platelet reac-
tivity and clopidogrel response in patients 75 Years Versus> 75 years undergoing percutaneous cor-
onary intervention for non-ST-segment elevation acute coronary syndrome. Am J Cardiol. 2011; 108:
1411–1416. doi: 10.1016/j.amjcard.2011.06.060 PMID: 21872198
PREDICT-STABLE Score
PLOS ONE | DOI:10.1371/journal.pone.0121620 March 23, 2015 12 / 13
31. Silvain J, Cayla G, Hulot J-S, Finzi J, Kerneis M, O’Connor SA, et al. High on-thienopyridine platelet re-
activity in elderly coronary patients: the SENIOR-PLATELET study. Eur Heart J. 2012; 33: 1241–1249.
doi: 10.1093/eurheartj/ehr407 PMID: 22067090
32. Angiolillo DJ, Fernández-Ortiz A, Bernardo E, Barrera Ramírez C, Sabaté M, Fernandez C, et al. Plate-
let aggregation according to body mass index in patients undergoing coronary stenting: should clopido-
grel loading-dose be weight adjusted? J Invasive Cardiol. 2004; 16: 169–174. PMID: 15152138
33. Bonello-Palot N, Armero S, Paganelli F, Mancini J, De Labriolle A, Bonello C, et al. Relation of body
mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according
to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Car-
diol. 2009; 104: 1511–1515. doi: 10.1016/j.amjcard.2009.07.015 PMID: 19932784
34. Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol
Ther. 1999; 37: 8–19. PMID: 10027478
35. Marcucci R, Gori AM, Paniccia R, Giglioli C, Buonamici P, Antoniucci D, et al. Residual platelet reactivi-
ty is associated with clinical and laboratory characteristics in patients with ischemic heart disease un-
dergoing PCI on dual antiplatelet therapy. Atherosclerosis. 2007; 195: e217–e223. PMID: 17555759
36. Peterson ED, Dai D, DeLong ER, Brennan JM, Singh M, Rao SV, et al. Contemporary mortality risk pre-
diction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardio-
vascular Data Registry. J Am Coll Cardiol. 2010; 55: 1923–1932. doi: 10.1016/j.jacc.2010.02.005
PMID: 20430263
37. DeMulder M, Gitt A, van Domburg R, Hochadel M, Seabra-Gomes R, Serruys PW, et al. EuroHeart
score for the evaluation of in-hospital mortality in patients undergoing percutaneous coronary interven-
tion. Eur Heart J. 2011; 32: 1398–1408. doi: 10.1093/eurheartj/ehr034 PMID: 21345854
38. Touchette MA, Slaughter RL. The effect of renal failure on hepatic drug clearance. DICP Ann Pharmac-
other. 1991; 25: 1214–1224.
39. Leblond F, Guévin C, Demers C, Pellerin I, Gascon-Barré M, Pichette V. Downregulation of hepatic cy-
tochrome P450 in chronic renal failure. J Am Soc Nephrol JASN. 2001; 12: 326–332. PMID: 11158222
40. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, et al. Ticagrelor versus clopidogrel in
acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient
Outcomes (PLATO) trial. Circulation. 2010; 122: 1056–1067. doi: 10.1161/CIRCULATIONAHA.109.
933796 PMID: 20805430
41. Chung I, Lip GYH. Platelets and heart failure. Eur Heart J. 2006; 27: 2623–2631. PMID: 17028108
42. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus
clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001–2015. PMID:
17982182
43. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopido-
grel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045–1057. doi: 10.1056/
NEJMoa0904327 PMID: 19717846
44. Reny J-L, Berdagué P, Poncet A, Barazer I, Nolli S, Fabbro-Peray P, et al. Antiplatelet drug response
status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Anti-
platelet Drug Resistances and Ischemic Events study. Circulation. 2012; 125: 3201–3210. doi: 10.
1161/CIRCULATIONAHA.111.085464 PMID: 22615340
45. Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, Goodman SG, et al. Platelet function during ex-
tended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the
TRILOGY ACS platelet function substudy. JAMA J AmMed Assoc. 2012; 308: 1785–1794.
46. Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C, et al. Rivaroxaban in patients with
a recent acute coronary syndrome. N Engl J Med. 2012; 366: 9–19. doi: 10.1056/NEJMoa1112277
PMID: 22077192
47. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, et al. Vorapaxar in the second-
ary prevention of atherothrombotic events. N Engl J Med. 2012; 366: 1404–1413. doi: 10.1056/
NEJMoa1200933 PMID: 22443427
PREDICT-STABLE Score
PLOS ONE | DOI:10.1371/journal.pone.0121620 March 23, 2015 13 / 13
